Active compounds identified as glyoxalase-I inhibitors. by MohammedBashar Al-Qazzan (22439236)

Subjects:

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Tolcapone diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Additional file 6 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Suggestive significant associations in the candidate gene approach. by Dai Nogimura (21445649)

Subjects:

Table 1_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Table 2_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Table 3_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Additional file 9 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 8 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Supplementary Table S2 from Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4⁺ T Cells by Signe Caksa (16745174)

Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 11 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 10 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

FK506 significantly potentiates caspofungin activity against tolerant <i>C. tropicalis</i> strains, reversing tolerance phenotypes in both <i>in vitro</i> and <i>in vivo</i> models... by Yongqin Wu (272012)

“…<p>(A) FK506 co-treatment completely inhibited multicellular aggregate formation in tolerant strains at both 6 h and 18 h post-caspofungin exposure. …”

Disruption of the <i>pcnB</i> gene encoding poly(A) polymerase PAP I decreases pYV PCN as well as T3SS expression and activity. by Katherine Schubert (5452712)